Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Tectonic Therapeutic, Inc. Director's Dealing 2018

Jun 21, 2018

33251_dirs_2018-06-20_386c4de5-0601-4b49-8946-540721d1f93c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: AVROBIO, Inc. (AVRO)
CIK: 0001681087
Period of Report: 2018-06-20

Reporting Person: Atlas Venture Fund X, L.P. (10% Owner)
Reporting Person: ATLAS VENTURE ASSOCIATES X, L.P. (10% Owner)
Reporting Person: Atlas Venture Associates X, LLC (10% Owner)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Series Seed Preferred Stock $ Common Stock (3333333) Indirect
Series A Preferred Stock $ Common Stock (12580199) Indirect
Series B Preferred Stock $ Common Stock (3740239) Indirect

Footnotes

F1: All series of Convertible Preferred Stock shall automatically convert on a 4.132-for-1 basis into shares of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering and have no expiration date

F2: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.